# Nano-delivery of miRNA inhibiting CENPF combined with cisplatin for bladder cancer treatment

## TL;DR

A new nanotherapy combining cisplatin and miR-205-5p improves bladder cancer treatment by targeting CENPF and reducing toxicity.

## Contribution

A novel PDA nanoparticle-based system co-delivers cisplatin and miR-205-5p to synergistically inhibit bladder cancer.

## Key findings

- Combination therapy reduces cisplatin toxicity while enhancing tumor cell death.
- miR-205-5p suppresses CENPF, a key cancer progression regulator, inhibiting tumor growth.
- The PDA system synergizes DNA damage and gene silencing for improved antitumor activity.

## Abstract

Bladder cancer (BCa) presents a substantial global health burden, with high rates of recurrence and metastasis that limit the effectiveness of current therapies. New therapeutic strategies are urgently needed. This study introduces a novel nanotherapeutic approach utilizing polydopamine (PDA) nanoparticles to co-deliver cisplatin and miR-205-5p for BCa treatment. Combination therapy reduces the dose-dependent toxicity of cisplatin while enhancing tumor cell cytotoxicity. miR-205-5p targets centromere protein F (CENPF), a key regulator of cancer progression. Overexpression of CENPF in BCa correlates with poor prognosis, and miR-205-5p-mediated suppression of CENPF expression inhibits tumor growth. The PDA-based system combines the DNA-damaging effects of cisplatin with the gene-silencing properties of miR-205-5p, resulting in synergistic antitumor activity. This multimodal strategy enhances therapeutic precision and efficacy, providing a promising solution for BCa treatment with significant clinical potential.

Bladder cancer (BCa) presents a substantial global health burden, with high rates of recurrence and metastasis that limit the effectiveness of current therapies.